Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.
Share
Why It Matters
A major analyst still likes BridgeBio but thinks the stock might be worth less money now. This shows the company is still on a good path, even if the near term looks trickier.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.